Impact of increased admission lipid levels on periprocedural myocardial injury following an elective percutaneous coronary intervention

Coronary Artery Disease

Volumn 26, Issue 4, 2015, Pages 333-340

  Buturak, Ali ^a   Degirmencioglu, Aleks ^a   Erturk, Mehmet ^a   Karakurt, Hüseyin ^a   Demir, Ali Riza ^a   Surgit, Ozgur ^a   Pusuroglu, Hamdi ^a   Akgul, Ozgur ^a   Serteser, Mustafa ^a   Norgaz, Tugrul ^a   Gorgulu, Sevket ^a  

^a ACIBADEM UNIVERSITY   (Turkey)

Author keywords

high sensitive troponin; hyperlipidemia; myocardial injury

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HIGH SENSITIVE TROPONIN T; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; TROPONIN T; UNCLASSIFIED DRUG; CHOLESTEROL; TROPONIN;

ADULT; ARTERY DIAMETER; ARTICLE; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG ELUTING STENT; FEMALE; HEART INFARCTION; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; IN-STENT RESTENOSIS; INCIDENCE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SMOKING; STABLE ANGINA PECTORIS; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; HYPERLIPIDEMIA; MYOCARDIAL INFARCTION; PREOPERATIVE PERIOD;

CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PREOPERATIVE PERIOD; TRIGLYCERIDES; TROPONIN;

EID: 84957606579     PISSN: 09546928     EISSN: 14735830     Source Type: Journal    
DOI: 10.1097/MCA.0000000000000235     Document Type: Article

References (28)

1. Selvanayagam JB, Porto I, Channon K, Petersen SE, Francis JM, Neubauer S, et al. Troponin elevations after percutaneous coronary intervention directly represents the extent of irreversible myocardial injury: insights from cardiovascular magnetic resonance imaging. Circulation 2005; 111:1027-1032.
2. Nienhuis MB, Ottervanger JP, Bilo HJ, Dikkeschei BD, Zijlstra F. Prognostic value of troponin after elective percutaneous coronary intervention: a meta-analysis. Catheter Cardiovasc Interv 2008; 71:318-324.
3. Testa L, Van Gaal WJ, Biondi Zoccai GG, Agostoni P, Latini RA, Bedogni F, et al. Myocardial infarction after percutaneous coronary intervention: a meta-analysis of troponin elevation applying the new universal definition. QJM 2009; 102:369-378.
4. Alcock RF, Roy P, Adorini K, Lau GT, Kritharides L, Lowe HC, et al. Incidence and determinants of myocardial infarction following percutaneous coronary interventions according to the revised Joint Task Force definition of troponin T elevation. Int J Cardiol 2010; 140:66-72.
5. Babu GG, Walker JM, Yellon DM, Hausenloy DJ. Peri-procedural myocardial injury during percutaneous coronary intervention: an important target for cardioprotection. Eur Heart J 2011; 32:23-31.
6. Thygesen K, Alpert JS, White HD. Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J 2007; 28:2525-2538.
7. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Writing Group on the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction; ESC Committee for Practice Guidelines (CPG). Third universal definition of myocardial infarction. Eur Heart J 2012; 33:2551-2567.
8. Apple FS, Collinson PO. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem 2012; 58:54-61.
9. Shaw RE, Anderson HV, Brindis RG, Krone RJ, Klein LW, McKay CR, et al. Development of a risk adjustment mortality model using the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR) experience: 1998-2000. J Am Coll Cardiol 2002; 39:1104-1112.
10. Smith SC Jr, Dove JT, Jacobs AK, Kennedy JW, Kereiakes D, Kern MJ, et al. ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines)-executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty). J Am Coll Cardiol 2001; 37:2215-2239.
11. Singh M, Lennon RJ, Roger VL, Rihal CS, Halligan S, Lerman A, et al. Relation of preprocedural statin therapy to in-hospital procedural complications following percutaneous coronary interventions in patients with hyperlipidemia. Am J Cardiol 2006; 98:325-330.
12. Mandadi VR, DeVoe MC, Ambrose JA, Prakash AM, Varshneya N, Gould RB, et al. Predictors of troponin elevation after percutaneous coronary intervention. Am J Cardiol 2004; 93:747-750.
13. Li XL, Li JJ, Guo YL, Zhu CG, Xu RX, Li S, et al. Association of preprocedural low-density lipoprotein cholesterol levels with myocardial injury after elective percutaneous coronary intervention. J Clin Lipidol 2014; 8:423-432.
14. Sattler KJ, Herrmann J, Yün S, Lehmann N, Wang Z, Heusch G, et al. High high-density lipoprotein-cholesterol reduces risk and extent of percutaneous coronary intervention-related myocardial infarction and improves long-term outcome in patients undergoing elective percutaneous coronary intervention. Eur Heart J 2009; 30:1894-1902.
15. Kyriakides ZS, Psychari S, Iliodromitis EK, Kolettis TM, Sbarouni E, Kremastinos DT. Hyperlipidemia prevents the expected reduction of myocardial ischemia on repeated balloon inflations during angioplasty. Chest 2002; 121:1211-1215.
16. Ungi I, Ungi T, Ruzsa Z, Nagy E, Zimmermann Z, Csont T, Ferdinandy P. Hypercholesterolemia attenuates the anti-ischemic effect of preconditioning during coronary angioplasty. Chest 2005; 128:1623-1628.
17. Ellis SG, Vandormael MG, Cowley MJ, DiSciascio G, Deligonul U, Topol EJ, et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. Circulation 1990; 82:1193-1202.
18. Cortese B, De Carlo M, De Matteis S, Rizza A, Giannini D, Palmieri C, et al. Distal embolisation during carotid stenting is predicted by circulating levels of LDL cholesterol and C-reactive protein. EuroIntervention 2014; 10:513-517.
19. Ito H, Motoyama S, Sarai M, Kawai H, Harigaya H, Kan S, et al. Characteristics of plaque progression detected by serial coronary computed tomography angiography. Heart Vessels 2014; 29:743-749.
20. Ferdinandy P. Myocardial ischaemia/reperfusion injury and preconditioning: effects of hypercholesterolaemia/hyperlipidaemia. Br J Pharmacol 2003; 138:283-285.
21. Ferdinandy P, Schulz R, Baxter GF. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 2007; 59:418-458.
22. Onody A, Csonka C, Giricz Z, Ferdinandy P. Hyperlipidemia induced by a cholesterol-rich diet leads to enhanced peroxynitrite formation in rat hearts. Cardiovasc Res 2003; 58:663-670.
23. Csont T, Balogh G, Csonka C, Boros I, Horváth I, Vigh L, Ferdinandy P. Hyperlipidemia induced by high cholesterol diet inhibits heat shock response in rat hearts. Biochem Biophys Res Commun 2002; 290:1535-1538.
24. Gordin J, Haider A, Swaminathan RV, Kim LK, Minutello RM, Bergman G, et al. Impact of long-term statin therapy on postprocedural myocardial infarction in patients undergoing nonemergency percutaneous coronary intervention. Am J Cardiol 2012; 110:1397-1404.
25. Patti G, Cannon CP, Murphy SA, Mega S, Pasceri V, Briguori C, et al. Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies. Circulation 2011; 123:1622-1632.
26. Norris DM, Anderson JR. Statin loading before percutaneous coronary intervention to reduce periprocedural myocardial infarction. Cardiol Rev 2012; 20:319-324.
27. Kaneko H, Yajima J, Oikawa Y, Tanaka S, Fukamachi D, Suzuki S, et al. Effects of statin treatment in patients with coronary artery disease and chronic kidney disease. Heart Vessels 2014; 29:21-28.
28. Underhill HR, Yuan C, Zhao XQ, Kraiss LW, Parker DL, Saam T, et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. Am Heart J 2008; 155: 584.e1-8.